亿帆医药涨2.12%，成交额5379.66万元，主力资金净流入507.23万元

Core Viewpoint - Yifan Pharmaceutical's stock has shown a year-to-date increase of 31.64%, with recent fluctuations indicating a slight decline over the past 20 and 60 days, suggesting potential volatility in the near term [1][2]. Financial Performance - For the first half of 2025, Yifan Pharmaceutical reported a revenue of 2.635 billion yuan, reflecting a year-on-year growth of 0.11%, while the net profit attributable to shareholders was 304 million yuan, marking a significant increase of 19.91% [2]. - Cumulatively, since its A-share listing, Yifan Pharmaceutical has distributed a total of 1.328 billion yuan in dividends, with 243 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Yifan Pharmaceutical stood at 46,600, a decrease of 0.46% from the previous period, while the average number of circulating shares per person increased by 0.46% to 18,048 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 25.5819 million shares, which is an increase of 2.4783 million shares compared to the previous period [3]. Stock Performance - As of October 15, Yifan Pharmaceutical's stock price was 13.98 yuan per share, with a trading volume of 53.7966 million yuan and a turnover rate of 0.46%, resulting in a total market capitalization of 17.005 billion yuan [1]. - The stock has experienced a net inflow of main funds amounting to 5.0723 million yuan, with significant buying and selling activity from large orders [1].